Opinion

Video

Atopic Dermatitis Treatment Advances and Changing Quality of Life Expectations

An expert on atopic dermatitis provides insights on how the evolving treatment landscape has impacted clinician and patient expectations.

Video content above is prompted by the following questions:

  • With the expansion of treatment options for atopic dermatitis (AD) in recent years, how have clinician and patient expectations changed regarding treatments and QoL improvements?
  • What recommendations do you have to manage patient expectations and discuss AD treatment goals with patients?
Related Videos
Discussing FDA Approval of Tapinarof Cream for Atopic Dermatitis, with John Browning, MD
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
New ‘Level Up’ Data on Upadacitinib (Rinvoq) for Atopic Dermatitis, with Christopher Bunick, MD, PhD
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
© 2024 MJH Life Sciences

All rights reserved.